[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590147":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":10,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":10,"enrollmentInfo":33,"targetDuration":36,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,11,13],{"label":9,"type":10,"description":10,"interventionNames":10},"First line treatment cohort",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Maintenance treatment cohort",{"label":14,"type":10,"description":10,"interventionNames":10},"Salvage treatment cohort",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Weili Zhao","CONTACT","+86 02164370045","zwl_trial@163.com",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhao Weili","M.D. and Ph.D","100590147",false,"NCT06963632","A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma","JOYCE","Inclusion Criteria:\n\n1. Voluntarily sign and acknowledge understanding of the Informed Consent Form\n2. Clinically confirmed diagnosis of peripheral T-cell lymphoma\n3. Inclusion of PTCL patients who initiated a Golidocitinib-based treatment regimen within the past 3 months\n4. Compliance with clinical management and provision of disease-related historical medical information required for the study, including but not limited to medical records, treatment history, and prior\u002Fprescribed therapeutic regimens\n\nExclusion Criteria:\n\n1. Poor patient adherence\n2. Investigator-deemed ineligibility for enrollment","ALL","18 Years",{"count":34,"type":35},1000,"ESTIMATED","1 Year","OBSERVATIONAL","This real-world study aims to evaluate the safety and efficacy of golidocitinib-based treatment regimens in patients with peripheral T-cell lymphoma (PTCL), without intervention in the selection of therapeutic strategies. A total of 1,000 PTCL patients are planned to be enrolled. After screening, eligible participants meeting the inclusion and exclusion criteria will be assigned to one of three predefined cohorts:\n\nCohort 1: Treatment-naïve patients with PTCL or NK\u002FT-cell lymphoma.\n\nCohort 2: Patients receiving maintenance therapy following remission after first-line induction treatment for PTCL.\n\nCohort 3: Patients with relapsed or refractory PTCL or relapsed\u002Frefractory NK\u002FT-cell lymphoma.\n\nThere is no cap on the number of participants in each cohort.",[40],"Peripheral T-cell Lymphoma (PTCL)","NOT_YET_RECRUITING","2025-05-06",{"date":44,"type":45},"2025-05-09","ACTUAL",{"date":47,"type":35},"2025-04-30",{"date":49,"type":35},"2027-12-31",{"name":5,"class":6}]